Financials

  • Market Capitalization 1.47 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
2.6
Price to sales ratio
1.04

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2170
TSHA
Taysha Gene Therapies, Inc. - Common Stock
5.38 USD-15.14%-16.07%-7.56%+103.02%1.55 B USD
2185
MLTX
MoonLake Immunotherapeutics - Class A Ordinary Shares
20.41 USD+0.25%+9.14%+8.28%+113.49%1.50 B USD
2235
XERS
Xeris Biopharma Holdings, Inc. - Common Stock
8.16 USD-2.16%-3.09%+20.18%+49.45%1.41 B USD
2263
INBX
Inhibrx Biosciences, Inc. - Common Stock
92.17 USD-0.90%-4.49%-3.10%+14.38%1.35 B USD

Frequently asked questions about Novavax, Inc. - Common Stock

What is the Novavax, Inc. - Common Stock stock price today?

The current price of Novavax, Inc. - Common Stock (NVAX) is 8.91. Over the past 24 hours, the stock has changed by -4.50%. Follow the NVAX chart for real-time price dynamics.

What is the stock ticker of Novavax, Inc. - Common Stock?

Novavax, Inc. - Common Stock trades under the ticker NVAX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Novavax, Inc. - Common Stock stock going up?

NVAX has changed by -4.60% over the last week, -2.84% over the last month, and +26.92% over the last year. Review the chart to see whether the current move is part of a broader trend.

Does Novavax, Inc. - Common Stock release financial reports?

Yes. You can track Novavax, Inc. - Common Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What was Novavax, Inc. - Common Stock net income for the last quarter?

Novavax, Inc. - Common Stock reported net income of -9.49 M for the last quarter. The previous quarter showed 17.53 M, which means net income changed by -154.15%.

How many employees does Novavax, Inc. - Common Stock have?

As of the latest available data, Novavax, Inc. - Common Stock has 749 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Novavax, Inc. - Common Stock stock?

You can buy Novavax, Inc. - Common Stock (NVAX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Novavax, Inc. - Common Stock stock?

Investing in Novavax, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the NVAX chart and related analysis on metatrader.com as part of your research.

Novavax, Inc. - Common Stock

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

News